Top

Published in:

01-01-2010 | Original Article

Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial

Authors: J. A. Cauley, A. Z. LaCroix, J. A. Robbins, J. Larson, R. Wallace, J. Wactawski-Wende, Z. Chen, D. C. Bauer, S. R. Cummings, R. Jackson

Published in: Osteoporosis International | Issue 1/2010

Abstract

Introduction

The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels.

Methods

We conducted a nested case–control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case–control pairs and a random sample of 519 all fracture case–control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years.

Results

There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo.

Conclusion

The effect of HT on fracture reduction is independent of estradiol and SHBG levels.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Jama 290:1729–1738CrossRefPubMed

Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 21:817–828CrossRefPubMed

The North American Menopause Society (2008) Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society 15:584

Rapuri PB, Gallagher JC, Haynatzki G (2004) Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab 89:4954–4962CrossRefPubMed

Huang AJ, Ettinger B, Vittinghoff E, Ensrud KE, Johnson KC, Cummings SR (2007) Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. J Bone Miner Res 22:1791–1797CrossRefPubMed

(1998) Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 19:61–109.

Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE (2003) The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77CrossRefPubMed

10.

Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL (2003) Implementation of the Women's Health Initiative study design. Ann Epidemiol 13:S5–S17CrossRefPubMed

11.

Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE (1999) Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165–173CrossRefPubMed

12.

Goebelsmann U, Stanczyk FZ, Brenner PF, Goebelsmann AE, Gentzschein EK, Mishell DR Jr (1979) Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone. Contraception 19:283–313CrossRefPubMed

13.

Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16:801–810CrossRefPubMed

14.

Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672CrossRefPubMed

15.

Sipila S, Heikkinen E, Cheng S, Suominen H, Saari P, Kovanen V, Alen M, Rantanen T (2006) Endogenous hormones, muscle strength, and risk of fall-related fractures in older women. J Gerontol A Biol Sci Med Sci 61:92–96PubMed

16.

Rinaldi S, Dechaud H, Toniolo P, Kaaks R (2002) Reliability and validity of direct radioimmunoassays for measurement of postmenopausal serum androgens and estrogens. IARC Sci Publ 156:323–325PubMed

17.

Robbins J, Aragaki A, Kiiperberg C, Watts N, Wactawski-Wende J, Jackson R, Lewis C, Chen Z, Stefanick M, Cauley JA (2007) Factors associated five year risk of hip fracture in postmenopausal women: WHI. JAMA 298:2389–2398CrossRefPubMed

18.

Cummings SR (2002) How drugs decrease fracture risk: lessons from trials. J Musculoskelet Neuronal Interact 2:198–200PubMed

19.

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMed

20.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10CrossRefPubMed

21.

Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed

22.

Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216–220CrossRefPubMed

23.

Lee JS, LaCroix AZ, Wu L, Cauley JA, Jackson RD, Kooperberg C, Leboff MS, Robbins J, Lewis CE, Bauer DC, Cummings SR (2008) Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women. J Clin Endocrinol Metab 93:1796–1803CrossRefPubMed

24.

Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W (2002) Sex hormone-binding globulin is synthesized in target cells. J Endocrinol 175:113–120CrossRefPubMed

25.

Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz H, Metzger J, Schweigert FJ, Luppa PB, Nykjaer A, Willnow TE (2005) Role of endocytosis in cellular uptake of sex steroids. Cell 122:751–762CrossRefPubMed

26.

Khosla S (2006) Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab 91:4764–4766CrossRefPubMed

27.

Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA (1999) Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol 69:481–485CrossRefPubMed

28.

Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA (2008) A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 93:1702–1710CrossRefPubMed

29.

Bjornerem A, Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Jorgensen L, Oian P, Seeman E, Straume B (2007) A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. Eur J Endocrinol 157:119–125CrossRefPubMed

30.

Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536CrossRefPubMed

31.

Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD (2000) Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res 15:1835–1841CrossRefPubMed

32.

Kuchuk NO, van Schoor NM, Pluijm SM, Smit JH, de Ronde W, Lips P (2007) The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf) 67:295–303CrossRef

33.

Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH, Pols HA (2004) Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 89:3261–3269CrossRefPubMed

34.

Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733–738CrossRefPubMed

Title: Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial
Authors: J. A. Cauley
A. Z. LaCroix
J. A. Robbins
J. Larson
R. Wallace
J. Wactawski-Wende
Z. Chen
D. C. Bauer
S. R. Cummings
R. Jackson
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0953-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

The effect of telomere length, a marker of biological aging, on bone mineral density in elderly population

Updated fracture incidence rates for the US version of FRAX®

Association analyses of vitamin D-binding protein gene with compression strength index variation in Caucasian nuclear families

Tracking of size-adjusted bone mineral content and bone area in boys and girls from 10 to 17 years of age

A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial

Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study